In 2010, “The Patient Protection and Affordable Care Act” (PPACA) was signed into law. As part of this legislation, the "Federal Physician Payment Act" ("Sunshine Act") was enacted. The Sunshine Act requires greater transparency into the interactions between pharmaceutical companies, physicians and teaching hospitals.
Starting in 2012, pharmaceutical companies will be required to track any educational gifts, payments and other transfers of value provided to physicians and teaching hospitals and to share this information in an annual disclosure report sent to the federal government. UCB, Inc. will also be providing physician payment summary reports on our Web site beginning in 2012. These physician payment reports are inclusive of payments and expenditures in alignment with the categories provided in the U.S. Sunshine Act.
UCB’s interactions with health care professionals are a vital component of ensuring that UCB delivers innovative medicines to patients. These interactions take many forms including clinical trial participation, consulting and advisory services, and on-going informational exchange with UCB colleagues. UCB also provides educational materials for health care professionals to benefit the delivery of health care to patients. To ensure that our interactions remain consistent and appropriate, UCB has adopted the PhRMA Code on Interactions with Healthcare Professionals.
UCB is committed to complying with all federal and state transparency and disclosure requirements, including the Sunshine Act. We anticipate that new developments and standards will emerge over time and UCB will ensure that our policies continue to align with industry and governmental. UCB will update our U.S. Web site with information, including the UCB physician payment reports, as information becomes available.
If you have any questions about transparency initiatives or reports, please contact the UCB Compliance Department at email@example.com.